MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

A

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Search

Twist Bioscience Corp

Open

SectorHealthcare

39.04 10.63

Overview

Share price change

24h

Current

Min

36.2

Max

39.56

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

Profit margin

-27.41

Employees

979

EBITDA

3.2M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+18.74% upside

Dividends

By Dow Jones

Next Earnings

2 Feb 2026

Market Stats

By TradingEconomics

Market Cap

231M

2.1B

Previous open

28.41

Previous close

39.04

News Sentiment

By Acuity

50%

50%

158 / 370 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

10 Jan 2026, 00:16 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Drops Merger With JenaValve

11 Jan 2026, 23:46 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

11 Jan 2026, 23:35 UTC

Market Talk

Oil Rises Amid Middle East Tensions -- Market Talk

11 Jan 2026, 23:25 UTC

Earnings

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11 Jan 2026, 22:05 UTC

Market Talk

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10 Jan 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Copper Is the Prize in Mining Megadeals -- WSJ

10 Jan 2026, 09:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

10 Jan 2026, 09:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

10 Jan 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jan 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 Jan 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

9 Jan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jan 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 Jan 2026, 21:43 UTC

Earnings
Acquisitions, Mergers, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 Jan 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 Jan 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 Jan 2026, 20:36 UTC

Acquisitions, Mergers, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 Jan 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 Jan 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 Jan 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9 Jan 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 Jan 2026, 19:58 UTC

Acquisitions, Mergers, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 Jan 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 Jan 2026, 19:38 UTC

Acquisitions, Mergers, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 Jan 2026, 19:31 UTC

Earnings

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 Jan 2026, 19:28 UTC

Earnings

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 Jan 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 Jan 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 Jan 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

18.74% upside

12 Months Forecast

Average 41.25 USD  18.74%

High 43 USD

Low 39 USD

Based on 5 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

158 / 370 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat